09966.HK
Alphamab Oncology
HKSE · Healthcare · Biotechnology · CN
HKD 8.77
−1.02%Year over year
Reported trailing growth
- Revenue
- +157.1%
- EBITDA
- +122.1%
- EBIT
- +98.8%
- EPS
- +114.8%
- Free cash flow
- +69.8%
- Operating cash flow
- +69.8%
Forward estimates
Based on analyst estimates
- Revenue
- -91.7%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +49.0%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026